| Year |
Citation |
Score |
| 2024 |
Al Yacoub ON, Zhang Y, Patankar PS, Standifer KM. Traumatic Brain Injury Induces Nociceptin/Orphanin FQ and Nociceptin Opioid Peptide Receptor Expression within 24 Hours. International Journal of Molecular Sciences. 25. PMID 38338936 DOI: 10.3390/ijms25031658 |
0.526 |
|
| 2023 |
Al Yacoub ON, Tarantini S, Zhang Y, Csiszar A, Standifer KM. The Nociceptin/Orphanin FQ peptide receptor antagonist, SB-612111, improves cerebral blood flow in a rat model of traumatic brain injury. Frontiers in Pharmacology. 14: 1272969. PMID 37920208 DOI: 10.3389/fphar.2023.1272969 |
0.439 |
|
| 2023 |
Al Yacoub ON, Awwad HO, Standifer KM. . The Journal of Pharmacology and Experimental Therapeutics. PMID 37442620 DOI: 10.1124/jpet.123.001664 |
0.787 |
|
| 2021 |
Al Yacoub ON, Awwad HO, Zhang Y, Standifer KM. Therapeutic potential of nociceptin/orphanin FQ peptide (NOP) receptor modulators for treatment of traumatic brain injury, traumatic stress, and their co-morbidities. Pharmacology & Therapeutics. 107982. PMID 34480968 DOI: 10.1016/j.pharmthera.2021.107982 |
0.771 |
|
| 2018 |
Zhang Y, Schalo I, Durand C, Standifer KM. Sex Differences in Nociceptin/Orphanin FQ Peptide Receptor-Mediated Pain and Anxiety Symptoms in a Preclinical Model of Post-traumatic Stress Disorder. Frontiers in Psychiatry. 9: 731. PMID 30670988 DOI: 10.3389/fpsyt.2018.00731 |
0.459 |
|
| 2016 |
Awwad HO, Durand CD, Gonzalez LP, Tompkins P, Zhang Y, Lerner MR, Brackett DJ, Sherry DM, Awasthi V, Standifer KM. Post-blast treatment with Nociceptin/Orphanin FQ Peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behavioural Brain Research. PMID 27793733 DOI: 10.1016/J.Bbr.2016.10.041 |
0.772 |
|
| 2015 |
Awwad HO, Gonzalez LP, Tompkins P, Lerner M, Brackett DJ, Awasthi V, Standifer KM. Blast Overpressure Waves Induce Transient Anxiety and Regional Changes in Cerebral Glucose Metabolism and Delayed Hyperarousal in Rats. Frontiers in Neurology. 6: 132. PMID 26136722 DOI: 10.3389/Fneur.2015.00132 |
0.715 |
|
| 2015 |
Zhang Y, Simpson-Durand CD, Standifer KM. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder British Journal of Pharmacology. 172: 571-582. DOI: 10.1111/bph.12701 |
0.475 |
|
| 2013 |
Donica CL, Awwad HO, Thakker DR, Standifer KM. Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ. Molecular Pharmacology. 83: 907-18. PMID 23395957 DOI: 10.1124/Mol.112.084632 |
0.655 |
|
| 2012 |
Zhang Y, Donica CL, Standifer KM. Sex differences in the Nociceptin/Orphanin FQ system in rat spinal cord following chronic morphine treatment. Neuropharmacology. 63: 427-33. PMID 22575074 DOI: 10.1016/J.Neuropharm.2012.04.028 |
0.715 |
|
| 2011 |
Donica CL, Ramirez VI, Awwad HO, Zaveri NT, Toll L, Standifer KM. Orphanin FQ/nociceptin activates nuclear factor kappa B. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 6: 617-25. PMID 21547539 DOI: 10.1007/S11481-011-9279-2 |
0.638 |
|
| 2011 |
Standifer K. Nociceptin orphanin FQ 1-13-NH 2 Xpharm: the Comprehensive Pharmacology Reference. 1-5. DOI: 10.1016/B978-008055232-3.62298-6 |
0.384 |
|
| 2008 |
Standifer KM, Ramirez VI. Selective utilization of G‐protein coupled receptor kinase (GRK) 2 and 3 in morphine‐induced μ opioid receptor internalization The Faseb Journal. 22: 617-617. DOI: 10.1096/fasebj.22.2_supplement.617 |
0.397 |
|
| 2007 |
Thakker DR, Altememi GF, Mandyam CD, Ibrahim H, Ramirez VI, Standifer KM. Naloxone benzoylhydrazone activates Extracellular Signal-Regulated Protein Kinases and modulates Nociceptin Opioid Peptide Receptor activity American Journal of Pharmacology and Toxicology. 2: 51-59. DOI: 10.3844/ajptsp.2007.51.59 |
0.488 |
|
| 2006 |
Desai AN, Salim S, Standifer KM, Eikenburg DC. Involvement of G protein-coupled receptor kinase (GRK) 3 and GRK2 in down-regulation of the alpha2B-adrenoceptor. The Journal of Pharmacology and Experimental Therapeutics. 317: 1027-35. PMID 16533872 DOI: 10.1124/jpet.105.098996 |
0.327 |
|
| 2005 |
Ozsoy HZ, Thakker DR, Standifer KM. Orphanin FQ/nociceptin potentiates [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin-Induced mu-opioid receptor phosphorylation. Molecular Pharmacology. 68: 447-56. PMID 15890842 DOI: 10.1124/mol.105.011536 |
0.535 |
|
| 2003 |
Mandyam CD, Thakker DR, Standifer KM. Mu-opioid-induced desensitization of opioid receptor-like 1 and mu-opioid receptors: differential intracellular signaling determines receptor sensitivity. The Journal of Pharmacology and Experimental Therapeutics. 306: 965-72. PMID 12750434 DOI: 10.1124/jpet.103.051599 |
0.485 |
|
| 2002 |
Thakker DR, Standifer KM. Induction of G protein-coupled receptor kinases 2 and 3 contributes to the cross-talk between mu and ORL1 receptors following prolonged agonist exposure. Neuropharmacology. 43: 979-90. PMID 12423667 DOI: 10.1016/S0028-3908(02)00145-4 |
0.489 |
|
| 2002 |
Thakker DR, Standifer KM. Orphanin FQ/nociceptin blocks chronic morphine-induced tyrosine hydroxylase upregulation. Brain Research. Molecular Brain Research. 105: 38-46. PMID 12399106 DOI: 10.1016/S0169-328X(02)00390-X |
0.423 |
|
| 2002 |
Mandyam CD, Thakker DR, Christensen JL, Standifer KM. Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk. The Journal of Pharmacology and Experimental Therapeutics. 302: 502-9. PMID 12130708 DOI: 10.1124/jpet.102.033159 |
0.514 |
|
| 2001 |
Mathis JP, Mandyam CD, Altememi GF, Pasternak GW, Standifer KM. Orphanin FQ/nociceptin and naloxone benzoylhydrazone activate distinct receptors in BE(2)-C human neuroblastoma cells. Neuroscience Letters. 299: 173-6. PMID 11165763 DOI: 10.1016/S0304-3940(01)01524-5 |
0.514 |
|
| 2000 |
Mandyam CD, Altememi GF, Standifer KM. beta-Funaltrexamine inactivates ORL1 receptors in BE(2)-C human neuroblastoma cells. European Journal of Pharmacology. 402: R1-37. PMID 10940375 DOI: 10.1016/S0014-2999(00)00497-0 |
0.428 |
|
| 1999 |
Standifer KM. Reduction of neurotransmitter receptor and G-protein expression in vivo and in vitro by antisense oligodeoxynucleotide treatment Methods in Enzymology. 314: 90-103. PMID 10565007 DOI: 10.1016/S0076-6879(99)14097-7 |
0.31 |
|
| 1997 |
Brown GP, Yang K, Ouerfelli O, Standifer KM, Byrd D, Pasternak GW. 3H-morphine-6β-glucuronide binding in brain membranes and an MOR-1- transfected cell line Journal of Pharmacology and Experimental Therapeutics. 282: 1291-1297. PMID 9316837 |
0.323 |
|
| 1997 |
Standifer KM, Pasternak GW. G proteins and opioid receptor-mediated signalling Cellular Signalling. 9: 237-248. PMID 9218123 DOI: 10.1016/S0898-6568(96)00174-X |
0.376 |
|
| 1996 |
Brooks AI, Standifer KM, Rossi GC, Mathis JP, Pasternak GW. Characterizing kappa3 opioid receptors with a selective monoclonal antibody. Synapse (New York, N.Y.). 22: 247-52. PMID 9132993 DOI: 10.1002/(Sici)1098-2396(199603)22:3<247::Aid-Syn7>3.0.Co;2-C |
0.372 |
|
| 1996 |
Ciszewska GR, Ginos JA, Charton M, Standifer KM, Brooks AI, Brown GP, Ryan-Moro JP, Berzetei-Gurske I, Toll L, Pasternak GW. Synthesis and characterization of substituted benzoylhydrazones of naloxone. Synapse (New York, N.Y.). 24: 193-201. PMID 8890461 DOI: 10.1002/(Sici)1098-2396(199610)24:2<193::Aid-Syn11>3.0.Co;2-# |
0.381 |
|
| 1996 |
Pasternak GW, Standifer KM. Pasternak and Standifer reply Trends in Pharmacological Sciences. 17: 217-218. DOI: 10.1016/0165-6147(96)81602-6 |
0.388 |
|
| 1995 |
Cheng J, Standifer KM, Tublin PR, Su W, Pasternak GW. Demonstration of κ3-opioid receptors in the SH-SY5Y human neuroblastoma cell line Journal of Neurochemistry. 65: 170-175. PMID 7790858 DOI: 10.1046/J.1471-4159.1995.65010170.X |
0.402 |
|
| 1995 |
Pan YX, Cheng J, Xu J, Rossi G, Jacobson E, Ryan-Moro J, Brooks AI, Dean GE, Standifer KM, Pasternak GW. Cloning and functional characterization through antisense mapping of a kappa 3-related opioid receptor. Molecular Pharmacology. 47: 1180-8. PMID 7603458 |
0.411 |
|
| 1995 |
Standifer KM, Jenab S, Su W, Chien CC, Pan YX, Inturrisi CE, Pasternak GW. Antisense oligodeoxynucleotides to the cloned δ receptor DOR-1: Uptake, stability, and regulation of gene expression Journal of Neurochemistry. 65: 1981-1987. PMID 7595481 DOI: 10.1046/J.1471-4159.1995.65051981.X |
0.403 |
|
| 1995 |
Pasternak GW, Standifer KM. Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology Trends in Pharmacological Sciences. 16: 344-350. PMID 7491712 DOI: 10.1016/S0165-6147(00)89068-9 |
0.422 |
|
| 1994 |
Standifer KM, Chien CC, Wahlestedt C, Brown GP, Pasternak GW. Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron. 12: 805-10. PMID 8161452 DOI: 10.1016/0896-6273(94)90333-6 |
0.393 |
|
| 1994 |
Standifer KM, Cheng J, Brooks AI, Honrado CP, Su W, Visconti LM, Biedler JL, Pasternak GW. Biochemical and pharmacological characterization of mu, delta and kappa 3 opioid receptors expressed in BE(2)-C neuroblastoma cells. The Journal of Pharmacology and Experimental Therapeutics. 270: 1246-55. PMID 7932177 |
0.373 |
|
| 1991 |
Kepler KL, Standifer KM, Paul D, Kest B, Pasternak GW, Bodnar RJ. Gender effects and central opioid analgesia. Pain. 45: 87-94. PMID 1677751 DOI: 10.1016/0304-3959(91)90168-W |
0.35 |
|
| 1990 |
Arjune D, Standifer KM, Pasternak GW, Bodnar RJ. Reduction by central beta-funaltrexamine of food intake in rats under freely-feeding, deprivation and glucoprivic conditions. Brain Research. 535: 101-9. PMID 1963340 DOI: 10.1016/0006-8993(90)91828-5 |
0.329 |
|
| 1990 |
Standifer KM, Paul D, Howard D, Levison J, Pasternak GW. Differential effects of dexamethasone on opioid receptor-mediated analgesia and selective binding New Leads in Opioid Research: Proceedings of the International Narcotics Research Conference. Ics914. 31-32. |
0.377 |
|
| Show low-probability matches. |